Forest Laboratories, Inc. (FRX) Announces Acquisition From Novexel of Additional Rights Related to NXL 104, a Novel Broad-Spectrum Beta-Lactamase Inhibitor
12/23/2009 9:05:23 AM
More...
|
AstraZeneca PLC (AZN) (JOBS) to Buy Novexel for $350 Million
12/23/2009 8:37:14 AM
More...
|
Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
11/6/2009 10:02:15 AM
More...
|
Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
9/11/2009 10:10:15 AM
More...
|
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
5/18/2009 10:00:03 AM
More...
|
Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush
3/26/2009 9:15:08 AM
More...
|
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
3/3/2009 8:25:24 AM
More...
|
Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
11/12/2008 8:29:50 AM
More...
|
Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America Meeting
10/27/2008 10:47:32 AM
More...
|
Novexel To Present Five Posters At The Joint Annual Interscience Conference On Antimicrobial Agents And Chemotherapy And The Infectious Disease Society Of America (ICAAC/IDSA) Meeting
10/24/2008 12:02:20 PM
More...
|
|